What are the main functions and therapeutic effects of erdafitinib?

Erdafitinib is an oral, small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family, specifically indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), particularly those with FGFR2 or FGFR3 gene alterations. The main function of this drug is to precisely target the FGFR signaling pathway and inhibit abnormal signal activation, thereby effectively preventing the growth, proliferation and invasion of tumor cells. It is an important breakthrough in the field of precision treatment of bladder cancer. Studies have shown that approximately 20% of urothelial cancer patients have FGFR gene mutations, fusions or amplifications. This subgroup of patients usually responds poorly to traditional chemotherapy or immunotherapy, and erdafitinib provides new treatment opportunities for these patients.

Clinically, erdafitinib inhibits tumor cell activity, induces cell apoptosis, and improves the tumor microenvironment by blocking the FGFR signaling chain. The FDA granted accelerated approval of erdafitinib based on data from the BLC2001 pivotal clinical trial for the treatment of patients with urothelial carcinoma with confirmed FGFR alterations who have progressed after at least one systemic treatment (such as platinum-based chemotherapy). In the trial, the objective response rate (ORR) of erdafitinib reached 40%, and some patients achieved disease control for several months or even more than a year, showing stable and durable anti-tumor activity.

The therapeutic effect of erdafitinib is not only reflected in prolonging progression-free survival (PFS), but also improving the patient's quality of life to a certain extent. For patient groups for whom traditional therapies are ineffective, erdafitinib provides a new, oral, relatively well-tolerated option. In addition, erdafitinib can evaluate drug activity by monitoring blood phosphorus levels (hyperphosphatemia is one of its biomarkers of drug efficacy) during treatment, thereby helping doctors dynamically adjust the dose and further optimize treatment effect and safety. It is worth noting that companion diagnostic testing must be performed before using erdafitinib to confirm the presence of FGFR gene mutations or fusions, which is the basis for ensuring successful treatment.

Reference materials：https://www.balversa.com/